Tags

Type your tag names separated by a space and hit enter

Aliskiren: clinical experience and future perspectives of renin inhibition.
Expert Opin Pharmacother. 2008 Apr; 9(5):825-37.EO

Abstract

BACKGROUND

Aliskiren, the first renin inhibitor with sufficient bioavailability for oral use, is now available to clinicians treating hypertension.

OBJECTIVE

The novel mechanism by which aliskiren works was used to provide understanding of its therapeutic and adverse effects.

METHODS

After reviewing physiology and preclinical studies, human studies of aliskiren in hypertension were reviewed. Effects of aliskiren on serum levels and enzymatic activity of renin were explored.

RESULTS/CONCLUSIONS

Aliskiren has antihypertensive efficacy similar to existing medications such as thiazide diuretics, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and can be used in drug combinations. Preclinical studies indicate possible cardioprotective and renoprotective effects, similar to other inhibitors of the renin-angiotensin cascade, but future studies are needed in humans.

Authors+Show Affiliations

Allegheny General Hospital, Division of Nephrology and Hypertension, 320 East North Avenue, Pittsburgh, PA 15212, USA. ksureshk@wpahs.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18345958

Citation

Sureshkumar, Kalathil K., et al. "Aliskiren: Clinical Experience and Future Perspectives of Renin Inhibition." Expert Opinion On Pharmacotherapy, vol. 9, no. 5, 2008, pp. 825-37.
Sureshkumar KK, Vasudevan S, Marcus RJ, et al. Aliskiren: clinical experience and future perspectives of renin inhibition. Expert Opin Pharmacother. 2008;9(5):825-37.
Sureshkumar, K. K., Vasudevan, S., Marcus, R. J., Hussain, S. M., & McGill, R. L. (2008). Aliskiren: clinical experience and future perspectives of renin inhibition. Expert Opinion On Pharmacotherapy, 9(5), 825-37. https://doi.org/10.1517/14656566.9.5.825
Sureshkumar KK, et al. Aliskiren: Clinical Experience and Future Perspectives of Renin Inhibition. Expert Opin Pharmacother. 2008;9(5):825-37. PubMed PMID: 18345958.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aliskiren: clinical experience and future perspectives of renin inhibition. AU - Sureshkumar,Kalathil K, AU - Vasudevan,Sapna, AU - Marcus,Richard J, AU - Hussain,Sabiha M, AU - McGill,Rita L, PY - 2008/3/19/pubmed PY - 2008/4/11/medline PY - 2008/3/19/entrez SP - 825 EP - 37 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 9 IS - 5 N2 - BACKGROUND: Aliskiren, the first renin inhibitor with sufficient bioavailability for oral use, is now available to clinicians treating hypertension. OBJECTIVE: The novel mechanism by which aliskiren works was used to provide understanding of its therapeutic and adverse effects. METHODS: After reviewing physiology and preclinical studies, human studies of aliskiren in hypertension were reviewed. Effects of aliskiren on serum levels and enzymatic activity of renin were explored. RESULTS/CONCLUSIONS: Aliskiren has antihypertensive efficacy similar to existing medications such as thiazide diuretics, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, and can be used in drug combinations. Preclinical studies indicate possible cardioprotective and renoprotective effects, similar to other inhibitors of the renin-angiotensin cascade, but future studies are needed in humans. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/18345958/Aliskiren:_clinical_experience_and_future_perspectives_of_renin_inhibition_ L2 - https://www.tandfonline.com/doi/full/10.1517/14656566.9.5.825 DB - PRIME DP - Unbound Medicine ER -